MediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6 months from the last treatment to 3 months from wound closure. The randomized phase II trial enrolled 73 patients with a variety of chronic and […]
Pharmaceuticals
Eli Lilly posts mixed Q4 earnings
Shares in Eli Lilly (NYSE:LLY) rose today after the drug manufacturer missed earnings expectations, but beat revenue estimates on Wall Street with its 4th quarter results. The Indianapolis-based company posted profits of $771.8 million on sales of $5.76 billion for the 3 months ended Dec. 31, for bottom-line growth of 61.3% on sales growth of 7.1% compared […]
Pfizer misses on Q4 earnings
Shares in Pfizer (NYSE:PFE) remained steady today after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results. The U.S. pharma giant posted profits of $775 million, or 13¢ per share, for the 3 months ended December 31, 2016, compared to a bottom-line loss of $172 million in the same period last year. Pfizer also reported revenues of $13.63 billion, a […]
Price collusion: Insulin makers face class-action lawsuit
A class-action lawsuit filed in the U.S. District Court of Massachusetts alleges that insulin makers Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other based on real market prices. In the last 5 years, the 3 companies […]
Merck becomes latest to offer insight into drug pricing practices
Last week, Merck (NYSE:MRK) released figures about its U.S. pricing practices, joining a growing list of companies that are revealing their pricing strategies amid criticism of the industry’s price hikes. The company didn’t release price increases of specific products, citing competition concerns. Merck said it would update the list annually at the beginning of each calendar year. […]
Novo Nordisk puts $145m into U.K. research center
(Reuters) – Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit. The Danish company said on Monday it would invest the money over 10 years in the center based at the University of Oxford, which will employ 100 […]
Endo cuts staff in restructuring effort
Endo International (NSDQ:ENDP) said today that it will cut 90 full-time positions from its workforce in an effort to restructure its generics and U.S. branded pharmaceutical businesses. The company said it will invest part of the cost savings that result from its restructuring into Endo’s core products and new product development. “Last year, Endo completed […]
Johnson & Johnson’s earnings disappoint, but pharma rev climbs
Shares in Johnson & Johnson (NYSE:JNJ) fell this week after the company missed the consensus top-line forecasts but pulled off earnings beats for both the 4th quarter and 2016. Pharmaceutical sales grew 6.5% for the full-year to $33.5 billion, with an operational increase of 7.4%. Domestic sales climbed nearly 10% and international sales increased 1.8%. New Brunswick, […]
Report: Novartis eyes sale for Alcon lens business
Novartis (NYSE:NVS) said yesterday that it is considering selling its Alcon eye care business and will buy back up to $5 billion worth of shares over the next 12 months, in an effort to reorganize after a tough year. The company’s profits dropped -11% to $936 million in the 3 months ended Dec. 31, while sales […]
Biogen beats Q4 earnings, misses on full-year rev forecast
Shares in Biogen (NSDQ:BIIB) rose this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected. The Cambridge, Mass.-based company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. […]